查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1224627

支气管扩张剂市场规模份额和趋势分析报告:按疾病(哮喘,COPD),给药途径(吸入,口服),药物类别,地区和分部预测2023-2030

Bronchodilators Market Size, Share & Trends Analysis Report By Disease (Asthma, COPD), By Route Of Administration (Inhalable, Oral), By Drug Class (Beta-Adrenergic, Anticholinergics), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10个工作天内

价格

支气管扩张剂市场增长和趋势

根据 Grand View Research, Inc. 的最新报告，全球支气管扩张剂市场到 2030 年将达到 287.5 亿美元，从 2023 年到 2030 年的复合年增长率 (CAGR) 将达到 3.29%。人口老龄化和越来越多的呼吸系统疾病患者推动了支气管扩张剂市场的增长。此外，慢性阻塞性肺疾病 (COPD) 和哮喘等呼吸系统疾病在老年人口中变得越来越普遍。

由于呼吸道疾病的增加，对支气管扩张剂的需求正在显着增长。吸烟人数激增增加了患哮喘和慢性阻塞性肺病等肺部疾病的高危人群。例如，根据世界卫生组织2021年的公告，全球有超过13亿烟民，据说其中80%位于中低收入国家。这些人会经历肺功能加速恶化和死亡率增加。根据美国肺臟协会的数据，17% 的哮喘患者是吸烟者，相比之下，13.7% 的非哮喘患者更有可能吸烟。这需要持续使用支气管扩张剂并加速对支气管扩张剂的需求。

此外，公共机构和私营公司正在加大力度提高公众意识。GOLD（慢性阻塞性肺病全球倡议）等国际组织与世界各地的公共卫生当局和医疗专业人员合作，以提高全世界对 COPD 的认识、改善治疗和预防。此外，AstraZeneca、Cipla 和 Teva 等公司已发起活动，通过“Get Real”、“#Laugh4Lungs”、“Inhalers are Right for Asthma”和“Inhaler is boon for Asthma”等社交媒体提高认识。正在扩大我们的活动。这些活动提高了患者的意识，鼓励更多地使用支气管扩张剂，并采取预防措施来挽救患者的生命。此外，随着区域市场参与者参与研发工作，为呼吸系统疾病患者开发有效的治疗方法，市场有望增长。

公司正在合作开发新疗法，以满足未满足的医疗需求。这使公司能够利用他们的资源来改进产品开发和供应链。此外，许多参与者都专注于产品发布以扩大他们的产品组合。例如，2021 年 9 月，AstraZeneca开始研究用于治疗哮喘患者的吸入皮质类固醇 (ICS) 布地奈德和 BETA2 激动剂 (SABA) 沙丁胺醇的联合製剂，如果获得批准，这可能是全球首个美国。预计它将作为 ICS/SABA 组合缓解哮喘吸入器。

支气管扩张剂市场报告要点

随着需求的增加，FDA 对仿製药的批准增加，BETA 肾上腺素能支气管扩张剂细分市场将在 2022 年主导市场细分

预计在预测期内口服将以最快的速度增长，因为它是临床医生和患者的第二首选给药方法

由于全球疾病增多，哮喘将在 2022 年主导市场细分

由于该地区主要市场参与者的存在、高度发达的医疗基础设施和更好的定价，北美将在 2022 年主导市场。

目录

第一章 调查方法和范围

  • 市场细分
  • 调查方法
  • 信息采购
    • 购买的数据库
    • 次要信息
    • 初步调查
    • 初步调查详情
  • 信息或数据分析
    • 数据分析模型
  • 市场製定和验证
  • 型号详情
    • 商品流向分析
      • 方法一：商品流动方法
      • 方法 2：使用自下而上的方法逐个国家/地区进行市场估算
  • 全球市场：复合年增长率计算
  • 调查假设
  • 二级信息列表
  • 主要信息列表
  • 目的
  • 缩略语表

第二章支气管扩张剂市场执行摘要

  • 市场快照
  • 段快照
  • 竞争格局的快照

3. 支气管扩张剂市场变量、趋势和范围

  • 支气管扩张剂市场谱系展望
    • 母公司市场展望
      • 全球哮喘和慢性阻塞性肺疾病市场
    • 辅助市场展望
      • 品牌仿製药市场
      • 院内感染用药市场
  • 绘製渗透率和增长前景
  • 市场驱动力分析
    • 老年人口不断增长
    • 肺部疾病患病率增加
    • 对治疗肺部疾病的认识不断提高
    • 吸烟人数增加
    • 玩家加大研发力度
    • 全球污染水平上升
  • 市场约束因素分析
    • 审批时间长，监管严格
    • 支气管扩张剂的副作用
  • SWOT 分析，按因素（政治和法律、经济、技术）
  • 波特五力分析
  • 监管框架

4 支气管扩张剂市场细分分析，按药物类别，2018-2030（百万美元）

  • 定义和范围
  • 支气管扩张剂市场：药物类别变化分析
    • BETA-肾上腺素能支气管扩张剂
    • 抗胆碱能支气管扩张药
    • 黄嘌呤衍生物

第 5 章支气管扩张剂市场-细分分析，按给药途径，2018-2030 年（百万美元）

  • 支气管扩张剂市场：给药途径变化分析
    • 口服
    • 鼻子（可吸入）
    • 可注射的

第 6 章支气管扩张剂市场-细分分析，按最终用途分类，2018-2030 年（百万美元）

  • 定义和范围
  • 支气管扩张剂市场：疾病变异分析
    • 哮喘
    • 慢性阻塞性肺疾病 (Copd)
    • 其他

第 7 章支气管扩张剂市场区域业务分析

  • 定义和范围
  • 2022 年和 2030 年区域市场份额分析
  • 区域市场仪表板
  • 区域市场快照
  • SWOT 分析，按因素（政治和法律、经济和技术）
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 多边环境协定
  • 2022-2030 年市场规模、预测和趋势分析
  • 北美
    • 美国
      • 主要国家动态
      • 监管框架
      • 竞争情景
      • 最近的发展
      • 投资场景
    • 加拿大
      • 主要国家动态
      • 监管框架
      • 竞争情景
      • 最近的发展
      • 投资场景
  • 欧洲
    • 英国
      • 主要国家动态
      • 监管框架
      • 竞争情景
      • 最近的发展
      • 投资场景
    • 德国
      • 主要国家动态
      • 监管框架
      • 竞争情景
      • 最近的发展
      • 投资场景
    • 西班牙
      • 主要国家动态
      • 监管框架
      • 竞争情景
      • 最近的发展
      • 投资场景
    • 法国
      • 主要国家动态
      • 监管框架
      • 竞争情景
      • 最近的发展
      • 投资场景
    • 意大利
      • 主要国家动态
      • 监管框架
      • 竞争情景
      • 最近的发展
      • 投资场景
    • 丹麦
      • 主要国家动态
      • 监管框架
      • 竞争情景
      • 最近的发展
      • 投资场景
    • 瑞典
      • 主要国家动态
      • 监管框架
      • 竞争情景
      • 最近的发展
      • 投资场景
    • 挪威
      • 主要国家动态
      • 监管框架
      • 竞争情景
      • 最近的发展
      • 投资场景
  • 亚太地区
    • 日本
      • 主要国家动态
      • 监管框架
      • 竞争情景
      • 最近的发展
      • 投资场景
    • 中国
      • 主要国家动态
      • 监管框架
      • 竞争情景
      • 最近的发展
      • 投资场景
    • 印度
      • 主要国家动态
      • 监管框架
      • 竞争情景
      • 最近的发展
      • 投资场景
    • 韩国
      • 主要国家动态
      • 监管框架
      • 竞争情景
      • 最近的发展
      • 投资场景
    • 泰国
      • 主要国家动态
      • 监管框架
      • 竞争情景
      • 最近的发展
      • 投资场景
    • 澳大利亚
      • 主要国家动态
      • 监管框架
      • 竞争情景
      • 最近的发展
      • 投资场景
  • 拉丁美洲
    • 巴西
      • 主要国家动态
      • 监管框架
      • 竞争情景
      • 最近的发展
      • 投资场景
    • 墨西哥
      • 主要国家动态
      • 监管框架
      • 竞争情景
      • 最近的发展
      • 投资场景
    • 阿根廷
      • 主要国家动态
      • 监管框架
      • 竞争情景
      • 最近的发展
      • 投资场景
  • 多边环境协定
    • 南非
      • 主要国家动态
      • 监管框架
      • 竞争情景
      • 最近的发展
      • 投资场景
    • 沙特阿拉伯
      • 主要国家动态
      • 监管框架
      • 竞争情景
      • 最近的发展
      • 投资场景
    • 阿拉伯联合酋长国
      • 主要国家动态
      • 监管框架
      • 竞争情景
      • 最近的发展
      • 投资场景
    • 科威特
      • 主要国家动态
      • 监管框架
      • 竞争情景
      • 最近的发展
      • 投资场景

第 8 章支气管扩张剂市场——竞争分析

  • 公司/竞争对手分类（主要创新者、市场领导者、初创企业）
  • 战略框架
  • 市场参与的分类
  • 主要市场进入者的最新发展和影响分析
  • 公司定位分析
  • 代理商名单
    • 主要客户
    • 上市公司
    • 民营企业

第 9 章支气管扩张剂市场-公司概况

  • 公司简介
    • Gsk Plc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Astrazeneca
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Teva Pharmaceutical Industries Ltd.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Cipla Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Mylan NV
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Merck & Co., Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Novartis Ag
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Boehringer Ingelheim International Gmbh.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Sun Pharmaceutical Industries Ltd.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Glenmark Pharmaceuticals Limited
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
Product Code: GVR-4-68040-027-4

Bronchodilators Market Growth & Trends:

The global bronchodilators market is expected to reach USD 28.75 billion by 2030 and is expected to expand at a compound annual growth rate (CAGR) of 3.29% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of the bronchodilators market is attributed to the increasing geriatric population and rising population with respiratory disorders. Moreover, respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma are more common among the elderly population.

The demand for bronchodilators is growing significantly, owing to the increasing incidence of respiratory disorders. The surging number of smokers is increasing the population with a heightened risk of lung conditions such as asthma and COPD. For instance, as per WHO in 2021, there are over 1.3 billion smokers globally with 80% of them situated in LMIC's. This population has an accelerated rate of deterioration in lung function along with intensified mortality rate. As per American Lung Association, 17% of the population with asthma are smokers which is 13.7% in the non-asthmatic population. This creates a need for persistent use of bronchodilators in patients, thereby, accelerating the demand for bronchodilators.

Moreover, there are increasing efforts from public and private organizations to increase awareness among the population. International organizations such as the Global Initiative for Chronic Obstructive Lung Disease (GOLD) are working with public health officials and healthcare professionals worldwide to increase awareness and improve the treatment and prevention of COPD around the world. Moreover, companies such as AstraZeneca, Cipla, Teva, and several others have been trying to spread awareness through social media platforms such as 'Get Real', #Laugh4Lungs', 'Inhalers are Right for Asthma', 'Inhaler is boon for Asthma', and many more. These campaigns help raise awareness and encourage patients towards using more bronchodilators and enable them to secure their lives by taking preventive measures. Furthermore, the market is expected to grow due to regional market players ongoing R&D efforts to develop an effective treatment for patients with respiratory disorders.

Companies are collaborating to develop novel treatments to address unmet medical needs. This enables businesses to use their resources to help with product development and supply chain improvements. Moreover, a number of players are also focusing on product launches in order to expand their product portfolio. For instance, in September 2021, AstraZeneca started working on a combination formulation of inhaled corticosteroid (ICS) budesonide and beta2-agonist (SABA) albuterol for the treatment of patients with Asthma, which if approved is expected to be the first ICS/SABA combo rescue inhaler for asthma in the U.S.

Bronchodilators Market Report Highlights:

  • Beta adrenergic bronchodilators segment held a dominant share in the market in 2022, owing to the increasing number of generic approvals by the FDA to meet the rising demands
  • Oral segment is projected to grow at the fastest rate over the forecast period attributable to it being the second most preferred mode of administration amongst clinicians and patients
  • Asthma segment held a dominant share of the market in 2022 owing to the increasing prevalence of target diseases worldwide
  • North America dominated the market in 2022, which is attributed to the presence of key market players in the region, highly developed healthcare infrastructure, better affordability

Table of Contents

Chapter 1 Methodology And Scope

  • 1.1 Market Segmentation
    • 1.1.1 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 Secondary Sources
    • 1.3.3 Primary Research
    • 1.3.4 Details Of Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach 1: Commodity Flow Approach
      • 1.6.1.2 Approach 2: Country Wise Market Estimation Using Bottom-Up Approach
  • 1.7 Global Market: Cagr Calculation
  • 1.8 Research Assumptions
  • 1.9 List Of Secondary Sources
  • 1.10 List Of Primary Sources
  • 1.11 Objectives
    • 1.11.1 Objective 1
    • 1.11.2 Objective 2
  • 1.12 List Of Abbreviations

Chapter 2 Bronchodilators Market - Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot
  • 2.3 Competitive Landscape Snapshot

Chapter 3 Bronchodilators Market Variables, Trends & Scope

  • 3.1 Bronchodilators Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
      • 3.1.1.1 Global Asthma And Copd Market
    • 3.1.2 Ancillary Market Outlook
      • 3.1.2.1 Branded Generics Market
      • 3.1.2.2 Hospital-Acquired Infection Therapeutics Market
  • 3.2 Penetration And Growth Prospect Mapping
  • 3.3 Market Driver Analysis
    • 3.3.1 Growing Geriatric Population
    • 3.3.2 Increasing Prevalence Of Lung Diseases
    • 3.3.3 Rising Awareness About Treatment Of Lung Diseases
    • 3.3.4. Increase In Number Of Smokers
    • 3.3.5. Escalating R&D Efforts By Players
    • 3.3.6. Heightened Pollution Levels Globally
  • 3.4 Market Restraint Analysis
    • 3.4.1 Long Approvals Times And Stringent Regulations
    • 3.4.2 Adverse Effects Of Bronchodilators
  • 3.5 Swot Analysis, By Factor (Political & Legal, Economic, And Technological)
  • 3.6 Porter's Five Forces Analysis
  • 3.7 Regulatory Framework

Chapter 4 Bronchodilators Market - Segment Analysis, By Drug Class, 2018 - 2030 (USD Million)

  • 4.1 Definition And Scope
  • 4.2 Bronchodilators Market: Drug Class Movement Analysis
    • 4.2.1 Beta-Adrenergic Bronchodilators
      • 4.2.1.1 Beta-Adrenergic Bronchodilators Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 4.2.2 Anticholinergic Bronchodilators
      • 4.2.2.1 Anticholinergic Bronchodilators Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 4.2.3 Xanthine Derivatives
      • 4.2.3.1 Xanthine Derivatives Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5 Bronchodilators Market - Segment Analysis, By Route Of Administration, 2018 - 2030 (USD Million)

  • 5.1 Bronchodilators Market: Route Of Administration Movement Analysis
    • 5.1.1 Oral
      • 5.1.1.1 Oral Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.1.2 Nasal (Inhalable)
      • 5.1.2.1 Nasal (Inhalable) Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.1.3 Injectable
      • 5.1.3.1 Injectable Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6 Bronchodilators Market - Segment Analysis, By End-Use, 2018 - 2030 (USD Million)

  • 6.1 Definition And Scope
  • 6.2 Bronchodilators Market: Disease Movement Analysis
    • 6.2.1 Asthma
      • 6.2.1.1 Asthma Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.2.2 Chronic Obstructive Pulmonary Disease (Copd)
      • 6.2.2.1 Chronic Obstructive Pulmonary Disease (Copd) Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.2.3 Others
      • 6.2.3.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 7 Bronchodilators Market - Regional Business Analysis

  • 7.1 Definition & Scope
  • 7.2 Regional Market Share Analysis, 2022 & 2030
  • 7.3 Regional Market Dashboard
  • 7.4 Regional Market Snapshot
  • 7.5 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
    • 7.5.1 North America
    • 7.5.2 Europe
    • 7.5.3 Asia Pacific
    • 7.5.4 Latin America
    • 7.5.5 MEA
  • 7.6 Market Size, & Forecasts, Trend Analysis, 2022 To 2030
  • 7.7 North America
    • 7.7.1 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.7.2 U.S.
      • 7.7.2.1 U.S. Bronchodilators Market, 2018 - 2030 (USD Million)
      • 7.7.2.2 Key Country Dynamics
      • 7.7.2.3 Regulatory Framework
      • 7.7.2.4 Competitive Scenario
      • 7.7.2.5 Recent Developments
      • 7.7.2.6 Investments Scenario
    • 7.7.3 Canada
      • 7.7.3.1 Canada Bronchodilators Market, 2018 - 2030 (USD Million)
      • 7.7.3.2 Key Country Dynamics
      • 7.7.3.3 Regulatory Framework
      • 7.7.3.4 Competitive Scenario
      • 7.7.3.5 Recent Developments
      • 7.7.3.6 Investments Scenario
  • 7.8 Europe
    • 7.8.1 Europe Bronchodilators Market, 2018 - 2030 (USD Million)
    • 7.8.2 U.K.
      • 7.8.2.1 U.K. Bronchodilators Market, 2018 - 2030 (USD Million)
      • 7.8.2.2 Key Country Dynamics
      • 7.8.2.3 Regulatory Framework
      • 7.8.2.4 Competitive Scenario
      • 7.8.2.5 Recent Developments
      • 7.8.2.6 Investments Scenario
    • 7.8.3 Germany
      • 7.8.3.1 Germany Bronchodilators Market, 2018 - 2030 (USD Million)
      • 7.8.3.2 Key Country Dynamics
      • 7.8.3.3 Regulatory Framework
      • 7.8.3.4 Competitive Scenario
      • 7.8.3.5 Recent Developments
      • 7.8.3.6 Investments Scenario
    • 7.8.4 Spain
      • 7.8.4.1 Spain Bronchodilators Market, 2018 - 2030 (USD Million)
      • 7.8.4.2 Key Country Dynamics
      • 7.8.4.3 Regulatory Framework
      • 7.8.4.4 Competitive Scenario
      • 7.8.4.5 Recent Developments
      • 7.8.4.6 Investments Scenario
    • 7.8.5 France
      • 7.8.5.1 France Bronchodilators Market, 2018 - 2030 (USD Million)
      • 7.8.5.2 Key Country Dynamics
      • 7.8.5.3 Regulatory Framework
      • 7.8.5.4 Competitive Scenario
      • 7.8.5.5 Recent Developments
      • 7.8.5.6 Investments Scenario
    • 7.8.6 Italy
      • 7.8.6.1 Italy Bronchodilators Market, 2018 - 2030 (USD Million)
      • 7.8.6.2 Key Country Dynamics
      • 7.8.6.3 Regulatory Framework
      • 7.8.6.4 Competitive Scenario
      • 7.8.6.5 Recent Developments
      • 7.8.6.6 Investments Scenario
    • 7.8.7 Denmark
      • 7.8.7.1 Denmark Bronchodilators Market, 2018 - 2030 (USD Million)
      • 7.8.7.2 Key Country Dynamics
      • 7.8.7.3 Regulatory Framework
      • 7.8.7.4 Competitive Scenario
      • 7.8.7.5 Recent Developments
      • 7.8.7.6 Investments Scenario
    • 7.8.8 Sweden
      • 7.8.8.1 Sweden Bronchodilators Market, 2018 - 2030 (USD Million)
      • 7.8.8.2 Key Country Dynamics
      • 7.8.8.3 Regulatory Framework
      • 7.8.8.4 Competitive Scenario
      • 7.8.8.5 Recent Developments
      • 7.8.8.6 Investments Scenario
    • 7.8.9 Norway
      • 7.8.9.1 Norway Bronchodilators Market, 2018 - 2030 (USD Million)
      • 7.8.9.2 Key Country Dynamics
      • 7.8.9.3 Regulatory Framework
      • 7.8.9.4 Competitive Scenario
      • 7.8.9.5 Recent Developments
      • 7.8.9.6 Investments Scenario
  • 7.9 Asia Pacific
    • 7.9.1 Asia-Pacific Bronchodilators Market, 2018 - 2030 (USD Million)
    • 7.9.2 Japan
      • 7.9.2.1 Japan Bronchodilators Market, 2018 - 2030 (USD Million)
      • 7.9.2.2 Key Country Dynamics
      • 7.9.2.3 Regulatory Framework
      • 7.9.2.4 Competitive Scenario
      • 7.9.2.5 Recent Developments
      • 7.9.2.6 Investments Scenario
    • 7.9.3 China
      • 7.9.3.1 China Bronchodilators Market, 2018 - 2030 (USD Million)
      • 7.9.3.2 Key Country Dynamics
      • 7.9.3.3 Regulatory Framework
      • 7.9.3.4 Competitive Scenario
      • 7.9.3.5 Recent Developments
      • 7.9.3.6 Investments Scenario
    • 7.9.4 India
      • 7.9.4.1 India Bronchodilators Market, 2018 - 2030 (USD Million)
      • 7.9.4.2 Key Country Dynamics
      • 7.9.4.3 Regulatory Framework
      • 7.9.4.4 Competitive Scenario
      • 7.9.4.5 Recent Developments
      • 7.9.4.6 Investments Scenario
    • 7.9.5 South Korea
      • 7.9.5.1 South Korea Bronchodilators Market, 2018 - 2030 (USD Million)
      • 7.9.5.2 Key Country Dynamics
      • 7.9.5.3 Regulatory Framework
      • 7.9.5.4 Competitive Scenario
      • 7.9.5.5 Recent Developments
      • 7.9.5.6 Investments Scenario
    • 7.9.6 Thailand
      • 7.9.6.1 Thailand Bronchodilators Market, 2018 - 2030 (USD Million)
      • 7.9.6.2 Key Country Dynamics
      • 7.9.6.3 Regulatory Framework
      • 7.9.6.4 Competitive Scenario
      • 7.9.6.5 Recent Developments
      • 7.9.6.6 Investments Scenario
    • 7.9.7 Australia
      • 7.9.7.1 Australia Bronchodilators Market, 2018 - 2030 (USD Million)
      • 7.9.7.2 Key Country Dynamics
      • 7.9.7.3 Regulatory Framework
      • 7.9.7.4 Competitive Scenario
      • 7.9.7.5 Recent Developments
      • 7.9.7.6 Investments Scenario
  • 7.10 Latin America
    • 7.10.1 Latin America Bronchodilators Market, 2018 - 2030 (USD Million)
    • 7.10.2 Brazil
      • 7.10.2.1 Brazil Bronchodilators Market, 2018 - 2030 (USD Million)
      • 7.10.2.2 Key Country Dynamics
      • 7.10.2.3 Regulatory Framework
      • 7.10.2.4 Competitive Scenario
      • 7.10.2.5 Recent Developments
      • 7.10.2.6 Investments Scenario
    • 7.10.3 Mexico
      • 7.10.3.1 Mexico Bronchodilators Market, 2018 - 2030 (USD Million)
      • 7.10.3.2 Key Country Dynamics
      • 7.10.3.3 Regulatory Framework
      • 7.10.3.4 Competitive Scenario
      • 7.10.3.5 Recent Developments
      • 7.10.3.6 Investments Scenario
    • 7.10.4 Argentina
      • 7.10.4.1 Argentina Bronchodilators Market, 2018 - 2030 (USD Million)
      • 7.10.4.2 Key Country Dynamics
      • 7.10.4.3 Regulatory Framework
      • 7.10.4.4 Competitive Scenario
      • 7.10.4.5 Recent Developments
      • 7.10.4.6 Investments Scenario
  • 7.11 MEA
    • 7.11.1 MEA Bronchodilators Market, 2018 - 2030 (USD Million)
    • 7.11.2 South Africa
      • 7.11.2.1 South Africa Bronchodilators Market, 2018 - 2030 (USD Million)
      • 7.11.2.2 Key Country Dynamics
      • 7.11.2.3 Regulatory Framework
      • 7.11.2.4 Competitive Scenario
      • 7.11.2.5 Recent Developments
      • 7.11.2.6 Investments Scenario
    • 7.11.3 Saudi Arabia
      • 7.11.3.1 Saudi Arabia Bronchodilators Market, 2018 - 2030 (USD Million)
      • 7.11.3.2 Key Country Dynamics
      • 7.11.3.3 Regulatory Framework
      • 7.11.3.4 Competitive Scenario
      • 7.11.3.5 Recent Developments
      • 7.11.3.6 Investments Scenario
    • 7.11.4 UAE
      • 7.11.4.1 UAE Bronchodilators Market, 2018 - 2030 (USD Million)
      • 7.11.4.2 Key Country Dynamics
      • 7.11.4.3 Regulatory Framework
      • 7.11.4.4 Competitive Scenario
      • 7.11.4.5 Recent Developments
      • 7.11.4.6 Investments Scenario
    • 7.11.5 Kuwait
      • 7.11.5.1 Kuwait Bronchodilators Market, 2018 - 2030 (USD Million)
      • 7.11.5.2 Key Country Dynamics
      • 7.11.5.3 Regulatory Framework
      • 7.11.5.4 Competitive Scenario
      • 7.11.5.5 Recent Developments
      • 7.11.5.6 Investments Scenario

Chapter 8 Bronchodilators Market - Competitive Analysis

  • 8.1 Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
  • 8.2 Strategy Framework
  • 8.3 Market Participation Categorization
  • 8.4 Recent Developments & Impact Analysis, By Key Market Participants
  • 8.5 Company Position Analysis
  • 8.6 List Of Distributors
    • 8.6.1 Key Customers
    • 8.6.2 Public Companies
    • 8.6.3 Private Companies

Chapter 9 Bronchodilators Market - Company Profiles

  • 9.1 Company Profiles
    • 9.1.1 Gsk Plc.
      • 9.1.1.1 Company Overview
      • 9.1.1.2 Financial Performance
      • 9.1.1.3 Product Benchmarking
      • 9.1.1.4 Strategic Initiatives
    • 9.1.2 Astrazeneca
      • 9.1.2.1 Company Overview
      • 9.1.2.2 Financial Performance
      • 9.1.2.3 Product Benchmarking
      • 9.1.2.4 Strategic Initiatives
    • 9.1.3 Teva Pharmaceutical Industries Ltd.
      • 9.1.3.1 Company Overview
      • 9.1.3.2 Financial Performance
      • 9.1.3.3 Product Benchmarking
      • 9.1.3.4 Strategic Initiatives
    • 9.1.4 Cipla Inc.
      • 9.1.4.1 Company Overview
      • 9.1.4.2 Financial Performance
      • 9.1.4.3 Product Benchmarking
      • 9.1.4.4 Strategic Initiatives
    • 9.1.5 Mylan N.V.
      • 9.1.5.1 Company Overview
      • 9.1.5.2 Financial Performance
      • 9.1.5.3 Product Benchmarking
      • 9.1.5.4 Strategic Initiatives
    • 9.1.6 Merck & Co., Inc.
      • 9.1.6.1 Company Overview
      • 9.1.6.2 Financial Performance
      • 9.1.6.3 Product Benchmarking
      • 9.1.6.4 Strategic Initiatives
    • 9.1.7 Novartis Ag
      • 9.1.7.1 Company Overview
      • 9.1.7.2 Financial Performance
      • 9.1.7.3 Product Benchmarking
      • 9.1.7.4 Strategic Initiatives
    • 9.1.8 Boehringer Ingelheim International Gmbh.
      • 9.1.8.1 Company Overview
      • 9.1.8.2 Financial Performance
      • 9.1.8.3 Product Benchmarking
      • 9.1.8.4 Strategic Initiatives
    • 9.1.9 Sun Pharmaceutical Industries Ltd.
      • 9.1.9.1 Company Overview
      • 9.1.9.2 Financial Performance
      • 9.1.9.3 Product Benchmarking
      • 9.1.9.4 Strategic Initiatives
    • 9.1.10 Glenmark Pharmaceuticals Limited
      • 9.1.10.1 Company Overview
      • 9.1.10.2 Financial Performance
      • 9.1.10.3 Product Benchmarking
      • 9.1.10.4 Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Regulatory Framework
  • Table 4 Global Bronchodilators Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 6 Global Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 7 Global Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
  • Table 8 North America Bronchodilators Market, By Country, 2018 - 2030, (USD Million)
  • Table 9 North America Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 10 North America Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 11 North America Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
  • Table 12 U.S. Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 13 U.S. Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 14 U.S. Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
  • Table 15 Canada Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 16 Canada Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 17 Canada Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
  • Table 18 Europe Bronchodilators Market, By Country, 2018 - 2030, (USD Million)
  • Table 19 Europe Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 20 Europe Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 21 Europe Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
  • Table 22 U.K. Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 23 U.K. Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 24 U.K. Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
  • Table 25 Germany Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 26 Germany Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 27 Germany Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
  • Table 28 France Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 29 France Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 30 France Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
  • Table 31 Spain Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 32 Spain Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 33 Spain Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
  • Table 34 Italy Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 35 Italy Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 36 Italy Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
  • Table 37 Denmark Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 38 Denmark Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 39 Denmark Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
  • Table 40 Sweden Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 41 Sweden Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 42 Sweden Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
  • Table 43 Norway Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 44 Norway Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 45 Norway Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Bronchodilators Market, By Country, 2018 - 2030, (USD Million)
  • Table 47 Asia Pacific Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
  • Table 50 Japan Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 51 Japan Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 52 Japan Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
  • Table 53 China Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 54 China Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 55 China Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
  • Table 56 Australia Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 57 Australia Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 58 Australia Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
  • Table 59 Thailand Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 60 Thailand Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 61 Thailand Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
  • Table 62 India Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 63 India Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 64 India Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
  • Table 65 South Korea Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 66 South Korea Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 67 South Korea Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
  • Table 68 Latin America Bronchodilators Market, By Country, 2018 - 2030, (USD Million)
  • Table 69 Latin America Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 70 Latin America Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 71 Latin America Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
  • Table 72 Mexico Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 73 Mexico Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 74 Mexico Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
  • Table 75 Brazil Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 76 Brazil Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 77 Brazil Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
  • Table 78 Argentina Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 79 Argentina Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 80 Argentina Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
  • Table 81 MEA Bronchodilators Market, By Country, 2018 - 2030, (USD Million)
  • Table 82 MEA Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 83 MEA Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 84 MEA Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
  • Table 85 South Africa Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 86 South Africa Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 87 South Africa Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 90 Saudi Arabia Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
  • Table 91 UAE Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 92 UAE Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 93 UAE Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Bronchodilators Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Bronchodilators Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 96 Kuwait Bronchodilators Market, By Disease, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Bronchodilators market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Bronchodilators market snapshot
  • Fig. 10 Penetration and growth prospect mapping for application, 2022 (USD million)
  • Fig. 11 Market Dynamics
  • Fig. 12 Bronchodilators market driver impact
  • Fig. 13 Bronchodilators market restraint impact
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 Bronchodilators market: Drug type outlook and key takeaways
  • Fig. 16 Beta-adrenergic bronchodilators market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 Anticholinergic bronchodilators market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Xanthine derivative market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Bronchodilators market: Cancer type outlook and key takeaways
  • Fig. 20 Bronchodilators market: Route of administration movement analysis
  • Fig. 21 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Nasal (Inhalation) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Bronchodilators market: Disease outlook and key takeaways
  • Fig. 25 Bronchodilators market: Disease movement analysis
  • Fig. 26 Asthma market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Chronic obstructive pulmonary disease (COPD) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Bronchodilators Market: Regional outlook and key takeaways
  • Fig. 30 Bronchodilators Market: Regional movement analysis
  • Fig. 31 North America
  • Fig. 32 North America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 U.S.
  • Fig. 34 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Canada
  • Fig. 36 Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Europe
  • Fig. 38 Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 U.K.
  • Fig. 40 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Germany
  • Fig. 42 Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 France
  • Fig. 44 France market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 Spain
  • Fig. 46 Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Italy
  • Fig. 48 Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Denmark
  • Fig. 50 Denmark market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Sweden
  • Fig. 52 Sweden market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 Norway
  • Fig. 54 Norway market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Asia Pacific
  • Fig. 56 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 57 Japan
  • Fig. 58 Japan market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 59 China
  • Fig. 60 China market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 61 India
  • Fig. 62 India market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 63 Thailand
  • Fig. 64 Thailand market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 65 Australia
  • Fig. 66 Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 67 South Korea
  • Fig. 68 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 69 Latin America
  • Fig. 70 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 71 Brazil
  • Fig. 72 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 73 Mexico
  • Fig. 74 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 75 Argentina
  • Fig. 76 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 77 MEA
  • Fig. 78 MEA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 79 South Africa
  • Fig. 80 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 81 Saudi Arabia
  • Fig. 82 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 83 UAE
  • Fig. 84 UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 85 Kuwait
  • Fig. 86 Kuwait market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 87 Ansoff Matrix
  • Fig. 88 Strategy mapping
  • Fig. 89 Company market share analysis, 2022
  • Fig. 90 Heat Map Analysis
  • Fig. 91 Market differentiators
  • Fig. 92 Heat Map Analysis